Gensight Biologics (XPAR:SIGHT) 5-Year EBITDA Growth Rate : 20.90% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics 5-Year EBITDA Growth Rate?

Gensight Biologics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was 21.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gensight Biologics was 25.00% per year. The lowest was -86.90% per year. And the median was 7.30% per year.

Competitive Comparison of Gensight Biologics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Gensight Biologics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's 5-Year EBITDA Growth Rate falls into.

Gensight Biologics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Gensight Biologics (XPAR:SIGHT) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Gensight Biologics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines